Clinical Values of Automated Electronic Alert for Acute Kidney Injury

Clinical Values of Automated Electronic Alert for Acute Kidney injury-a Prospective ,Randomly Controlled Cohort Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02793167

Enrollment

2000

Registered

2016-06-08

Start date

2016-03-31

Completion date

2022-06-30

Last updated

2023-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

acute kidney injury, medication alert systems

Brief summary

Acute kidney injury (AKI) is common, serious and expensive.It is associated with significant mortality, morbidity and increased length of hospital stay.To improve clinical outcomes of AKI by early detection and timely referral to the renal,the investigators developed an electronic alert system which identifies all cases of AKI occurring in patients over 18 years.The system was also designed to collect data on AKI incidence one of the biggest tertiary hospital in China.

Detailed description

A prospective, randomly controlled cohort study will be conducted agmong the patients with AKI who are detected by the use of AKI sniffer. The investigators chose to assess all inpatient serum creatinine results using a combination of KDIGO criteria. The investigators randomly divided the patients into two groups: 1. Usual care : patients will receive standard clinical care by the primary physicians 2. AKI alert : an AKI alert will be sent to the the doctor in charge. Our team of kidney experts would give a suggestion if the the doctor in charge issue consultation applications.

Interventions

DEVICEAKI alert

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* adult patients with an Alert for AKI(based on KDIGO guidelines)

Exclusion criteria

* patients already on dialysis for AKI at the time of alert * patients with End stage renal disease * patients \<18 years of age * patients dissenting from participation according to the Ethics application

Design outcomes

Primary

Measure	Time frame	Description
Adverse events during hospitalization	from start of AKI to discharge,up to 4 weeks	cardiac shock/ need for intensive care/ cardiopulmonary resuscitation/ cardiac death/ death
Incidence of cardiovascular disease and its occurrence time followed up for 1 years	One year after discharge	heart failure/ acute coronary syndrome/ readmission/cardiac readmission/ cardiovascular intervention or surgery
The AKI outcome and its occurrence time followed up for 1 years	One year after discharge	AKI recovery/stop renal replacement therapy
AKI recovery/stop renal replacement therapy	from start of AKI to discharge,up to 4 weeks	Glomerular filtration rate decreased/ new occurrence proteinuria/ original proteinuria aggravation

Secondary

Measure	Time frame
Diagnostic rate of AKI at discharge	from start of AKI to discharge,up to 4 weeks
Follow-up rate after discharge	One year after discharge
Proportion of nephrology referral	from start of AKI to discharge,up to 4 weeks

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026